Impact of a medicaid copayment policy on prescription drug and health services utilization in a fee-for-service medicaid population

Medical Care

Volumn 46, Issue 6, 2008, Pages 565-572

  Hartung, Daniel M ^a   Carlson, Matthew J ^b   Kraemer, Dale F ^a,c   Haxby, Dean G ^a   Ketchum, Kathy L ^a   Greenlick, Merwyn R ^c  

^a OREGON STATE UNIVERSITY   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cost sharing; Drug utilization; Medicaid

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COST; ECONOMICS; FEMALE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; INSURANCE; LEGAL ASPECT; MALE; MEDICAID; MEDICAL FEE; MIDDLE AGED; PHARMACY; UNITED STATES; UTILIZATION REVIEW;

ADULT; AGED; COHORT STUDIES; COST SHARING; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH POLICY; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICAID; MIDDLE AGED; OREGON; PHARMACEUTICAL SERVICES; PROGRAM EVALUATION; UNITED STATES;

EID: 44449118571     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181734a77     Document Type: Article

References (36)

1. Novartis Pharmacy Benefit Report. Parsippany, NJ: Novartis Pharmceutical Corp., Inc.; 2000.
2. Crowley JS, Ashner D, Elam L. Medicaid Outpatient Prescription Drug Benefits: Findings From a National Survey. Washington, DC: Kaiser Commission on Medicaid and the Uninsured; 2003.
3. Code of Federal Regulations. Payment for Services. 21 C.F.R. Sect. 447. Vol 54. Washington, DC: Government Printing Office; 2006. Available at: http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&tpl=/ecfrbrowse/ Title42/42cfr447_main_02.tpl.
4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61-69.
5. Nelson AA Jr, Reeder CE, Dickson WM. The effect of a medicaid drug copayment program on the utilization and cost of prescription services. Med Care. 1984;22:724-736.
6. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a medicaid population. Inquiry. 1985;22:396-403.
7. Nelson AA Jr, Quick MR. Copayment for pharmaceutical services in a medicaid program. Contemp Pharm Pract. 1980;3:37-42.
8. Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
9. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
10. Carbaugh AL, Elias R, Rowland D. Aid to people with disabilities: Medicaid's growing role. Annu Rev Public Health. 2006;27:417-442.
11. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
12. Deficit Reduction Act of 2005: Implications For Medicaid. Washington, DC: Henry J. Kaiser Family Foundation; 2006.
13. Soumerai SB, Ross-Degnan D, Fortess EE, et al. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q. 1993;71:217-252.
14. Ray WA. Policy and program analysis using administrative databases. Ann Intern Med. 1997;127:712-718.
15. Hartung DM, Ketchum KL, Haxby DG. An evaluation of Oregon's evidence-based practitioner-managed prescription drug plan. Health Aff. 2006;25:1423-1432.
16. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2007;164:1198-1205.
17. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol. 1989;42:937-945.
18. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
20. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079; discussion 1081-1090.
21. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864.
22. Definitions of Rural & Assessing Healthcare Needs. Oregon Health & Science University Office of Rural Health; 2003.
23. Kennedy P. A Guide to Econometrics. 5th ed. Cambridge, MA: MIT Press; 2003.
24. Veney JE, Kaluzny AD. Evaluation of Decision Making for Health Services. Chicago, IL: Health Administration Press; 1998.
25. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309.
26. Neter J, Kutner MH, Nachtsheim CJ, et al. Applied Linear Regression Models. Chicago, IL: Irwin; 1996.
27. Carlson MJ, Wright BJ. The Impact of Program Changes on Enrollment, Access, and Utilization in the Oregon Health Plan Standard Population. Portland: The Office for Oregon Health Policy and Research; 2005.
28. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for costrelated medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22:864-871.
29. Piette JD, Heisler M, Ganoczy D, et al. Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatr Serv. 2007;58:207-212.
30. Hulley SB, Cummings SR, Browner WS, et al. Designing Clinical Research: An Epidemiologic Approach. Philadelphia, PA: Lippincot Williams & Wilkins; 2001.
31. McKenzie DA, Semradek J, McFarland BH, et al. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol. 2000;53:1248-1257.
32. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev. 1990;12:87-107.
33. Ray WA, Griffin MR. Use of medicaid data for pharmacoepidemiology. Am J Epidemiol. 1989;129:837-849.
34. Federspiel CF, Ray WA, Schaffner W. Medicaid records as a valid data source: the Tennessee experience. Med Care. 1976;14:166-172.
35. Hennessy S, Bilker WB, Weber A, et al. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf. 2003;12:103-111.
36. Braithwaite RS, Rosen AB. Linking cost sharing to value: an unrivaled yet unrealized public health opportunity. Ann Intern Med. 2007;146:602-605.